Alphamab Oncology (9966.HK)
- Previous Close
7.170 - Open
7.170 - Bid 7.280 x --
- Ask 7.330 x --
- Day's Range
6.980 - 7.360 - 52 Week Range
2.000 - 8.730 - Volume
3,269,000 - Avg. Volume
5,461,287 - Market Cap (intraday)
7.061B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
40.78 - EPS (TTM)
0.180 - Earnings Date Mar 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.79
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology biologics. The company commercializes KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENQEIDA brand name. Its product pipeline includes KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antiboday that is in Phase III clinical trials for treatment of HER2-positive breast cancer and HER2- positive gastric cancer or gastroesophageal junction cancer; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in Phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; JSKN016, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced malignant solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
www.alphamabonc.comRecent News: 9966.HK
View MorePerformance Overview: 9966.HK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9966.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9966.HK
View MoreValuation Measures
Market Cap
7.06B
Enterprise Value
5.57B
Trailing P/E
40.21
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.51
Price/Book (mrq)
3.59
Enterprise Value/Revenue
8.11
Enterprise Value/EBITDA
20.49
Financial Highlights
Profitability and Income Statement
Profit Margin
25.99%
Return on Assets (ttm)
2.88%
Return on Equity (ttm)
9.49%
Revenue (ttm)
640.08M
Net Income Avi to Common (ttm)
166.34M
Diluted EPS (ttm)
0.180
Balance Sheet and Cash Flow
Total Cash (mrq)
1.57B
Total Debt/Equity (mrq)
10.15%
Levered Free Cash Flow (ttm)
139.12M